{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:42:04Z","timestamp":1791510124397,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12072-022-10436-2","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T19:13:37Z","timestamp":1667070817000},"page":"225-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States"],"prefix":"10.1007","volume":"17","author":[{"given":"Allen D.","family":"Dao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vy H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsey","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-4989","authenticated-orcid":false,"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"issue":"1","key":"10436_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384","journal-title":"Hepatology"},{"issue":"3","key":"10436_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173499","volume":"12","author":"MH Le","year":"2017","unstructured":"Le MH, Devaki P, Ha NB, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS ONE. 2017;12(3): e0173499","journal-title":"PLoS ONE"},{"issue":"1","key":"10436_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10436_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/joim.13069","volume":"288","author":"B Zou","year":"2020","unstructured":"Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999\u20132016. J Intern Med. 2020;288(1):139\u2013151","journal-title":"J Intern Med"},{"key":"10436_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","volume":"91","author":"ZM Younoussi","year":"2012","unstructured":"Younoussi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine. 2012;91:319\u2013327","journal-title":"Medicine"},{"key":"10436_CR6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1210\/jc.2015-3444","volume":"101","author":"AK Loomis","year":"2016","unstructured":"Loomis AK, Kabadi S, Preiss D, et al. Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record propsective studies. J Clin Endocrinal Metab. 2016;101:945\u2013952","journal-title":"J Clin Endocrinal Metab"},{"issue":"1","key":"10436_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u2013209","journal-title":"J Hepatol"},{"key":"10436_CR8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VWS, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889\u2013919. https:\/\/doi.org\/10.1007\/s12072-020-10094-2","journal-title":"Hepatol Int"},{"key":"10436_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/ajg.2016.318","volume":"112","author":"A Feldman","year":"2017","unstructured":"Feldman A, Eder SK, Felder TK, Kedenko L, Paulweber B, Stadlmayr A, et al. Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver. Am J Gastroenterol. 2017;112:102\u2013110","journal-title":"Am J Gastroenterol"},{"key":"10436_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s12072-021-10147-0","volume":"15","author":"YM Cheng","year":"2022","unstructured":"Cheng YM, Kao JH, Wang CC. The metabolic profiles and body composition of lean metabolic associated fatty liver disease. Hepatol Int. 2022;15:405\u2013412","journal-title":"Hepatol Int"},{"key":"10436_CR11","unstructured":"NCHS. National Health and Nutrition Examination Survey (NHANES). Available at: https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/Nhanes3\/Default.aspx. Accessed Aug 18, 2021)."},{"key":"10436_CR12","unstructured":"National Health and Nutrition Examination Survey, Third National Health and Nutrition Examination Survey: Hepatic\/Gallbladder Ultrasound and Hepatic Steatosis (HGUHS). https:\/\/wwwn.cdc.gov\/nchs\/Data\/Nhanes3\/34A\/HGUHS.htm. Accessed Aug 23, 2021."},{"key":"10436_CR13","unstructured":"National Health and Nutrition Examination Survey (NHANES) III, Hepatic Steatosis Ultrasound Images Assessment Procedures Manual 2010. https:\/\/www.cdc.gov\/nchs\/data\/nhanes\/nhanes3\/hepatic_steatosis_ultrasound_procedures_manual.pdf. Accessed Aug 23, 2021."},{"issue":"4","key":"10436_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846\u2013854","journal-title":"Hepatology"},{"issue":"6","key":"10436_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u20131325","journal-title":"Hepatology"},{"key":"10436_CR16","unstructured":"NCHS. Key Concepts About Weighting in NHANES. Available at: https:\/\/www.cdc.gov\/nchs\/tutorials\/NHANES\/SurveyDesign\/Weighting\/OverviewKey.htm. Accessed Aug 23, 2021."},{"key":"10436_CR17","unstructured":"StataCorp LP. Stata survival analysis and epidemiological tables reference manual; 1985. Accessed Aug 23, 2021."},{"issue":"1 Suppl","key":"10436_CR18","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-64. https:\/\/doi.org\/10.1016\/j.jhep.2014.12.012","journal-title":"J Hepatol"},{"key":"10436_CR19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cgh.2011.12.039","volume":"10","author":"M Stepanova","year":"2012","unstructured":"Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012;10:646\u2013650","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10436_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d6891","volume":"343","author":"M Lazo","year":"2011","unstructured":"Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011;343: d6891","journal-title":"BMJ"},{"issue":"4","key":"10436_CR21","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/hep.30908","volume":"71","author":"F Chen","year":"2020","unstructured":"Chen F, Esmaili S, Rogers GB, Bugianesi E, Petta S, Marchesini G, et al. Lean NAFLD: a distinct entity shaped by differential metabolic adaptation. Hepatology. 2020;71(4):1213\u20131227. https:\/\/doi.org\/10.1002\/hep.30908","journal-title":"Hepatology"},{"issue":"11","key":"10436_CR22","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/jgh3.12658","volume":"5","author":"S Alam","year":"2021","unstructured":"Alam S, Eslam M, Skm Hasan N, Anam K, Chowdhury MAB, Khan MAS, et al. Risk factors of nonalcoholic fatty liver disease in lean body mass population: a systematic review and meta-analysis. JGH Open. 2021;5(11):1236\u20131249. https:\/\/doi.org\/10.1002\/jgh3.12658","journal-title":"JGH Open"},{"issue":"1","key":"10436_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2337\/cd18-0026.PMID:30705499;PMCID:PMC6336127","volume":"37","author":"P Golabi","year":"2019","unstructured":"Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin Diabetes. 2019;37(1):65\u201372. https:\/\/doi.org\/10.2337\/cd18-0026.PMID:30705499;PMCID:PMC6336127","journal-title":"Clin Diabetes"},{"issue":"6","key":"10436_CR24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, St\u00e5l P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265\u20131273. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.027","journal-title":"J Hepatol"},{"issue":"5","key":"10436_CR25","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557\u20131565. https:\/\/doi.org\/10.1002\/hep.29085","journal-title":"Hepatology"},{"issue":"5","key":"10436_CR26","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547\u20131554. https:\/\/doi.org\/10.1002\/hep.27368","journal-title":"Hepatology"},{"issue":"6","key":"10436_CR27","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, Hagstr\u00f6m H, Nasr P, Schattenberg JM, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta analysis. Gastroenterology. 2020;158(6):1611-1625.e12. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.043","journal-title":"Gastroenterology"},{"issue":"6","key":"10436_CR28","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","volume":"75","author":"D Kim","year":"2021","unstructured":"Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75(6):1284\u20131291. https:\/\/doi.org\/10.1016\/j.jhep.2021.07.035","journal-title":"J Hepatol"},{"issue":"3","key":"10436_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","volume":"160","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2021;160(3):912\u2013918. https:\/\/doi.org\/10.1053\/j.gastro.2020.11.051","journal-title":"Gastroenterology"},{"key":"10436_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1707","author":"JM Paik","year":"2021","unstructured":"Paik JM, Mir S, Alqahtani SA, Younossi Y, Ong JP, Younossi ZM. Dietary risks for liver mortality in NAFLD: global burden of disease data. Hepatol Commun. 2021. https:\/\/doi.org\/10.1002\/hep4.1707","journal-title":"Hepatol Commun"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10436-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-022-10436-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10436-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T17:45:28Z","timestamp":1675359928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-022-10436-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10436"],"URL":"https:\/\/doi.org\/10.1007\/s12072-022-10436-2","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]},"assertion":[{"value":"9 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mindie H. Nguyen: Research support: Pfizer, Enanta, Gilead, Exact Sciences, Vir Biotech, Helio Health, National Cancer Institute, Glycotest, B. K. Kee Foundation; Consulting and\/or Advisory Board: Intercept, Exact Science, Gilead, GSK, Eli Lilly, Laboratory of Advanced Medicine, Janssen. Ramsey Cheung: Research support: Gilead. Allen D. Dao, Vy H. Nguyen and Takanori Ito have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All participants gave written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}